Procalcitonin in heart failure: hic et nunc

Area of Science:

• Biomarkers in cardiovascular disease
• Clinical chemistry and diagnostics
• Inflammation and infection markers

Background:

• Procalcitonin (PCT) has been studied in heart failure (HF) since 1999, but its role remains under investigation.
• HF patients exhibit higher plasma PCT concentrations compared to healthy individuals.
• PCT levels correlate with HF severity and are linked to adverse outcomes like mortality and rehospitalization, even without infection.

Purpose of the Study:

• To review the current evidence on the utility and limitations of procalcitonin (PCT) as a biomarker in heart failure (HF).
• To summarize the association between PCT levels and HF severity and patient outcomes.
• To evaluate the impact of PCT-guided antibiotic treatment in HF patients.

Main Methods:

• Literature review of published studies on procalcitonin (PCT) in heart failure (HF).
• Analysis of data concerning PCT levels, HF severity, patient outcomes, and antibiotic treatment strategies.
• Synthesis of evidence regarding the diagnostic and prognostic value of PCT in HF.

Main Results:

• Elevated plasma PCT concentrations are observed in HF patients compared to healthy controls.
• Higher PCT levels in HF patients are associated with increased mortality and rehospitalization rates, irrespective of infection.
• PCT-guided antibiotic therapy in HF patients has been shown to reduce antibiotic duration and improve clinical outcomes.

Conclusions:

• Procalcitonin (PCT) is a valuable biomarker in heart failure (HF), indicating disease severity and prognosis.
• PCT levels can help stratify risk and guide therapeutic decisions in HF patients.
• PCT-guided antibiotic management offers benefits in HF, reducing unnecessary antibiotic exposure and enhancing patient outcomes.